Schizophrenia. A disorder in which there is an insidious but progressive development of oddities of conduct, inability to meet the demands of society, and decline in total performance. The characteristic negative features of residual schizophrenia (e.g. blunting of affe
Conditions
Interventions
Intervention 1: In Group A, 600000 IU vitamin D supplementation is added intramuscular to standard atypical antipsychotic drug regimens monthly for three months. Intervention 2: In Group B, as control
Treatment - Drugs
In Group A, 600000 IU vitamin D supplementation is added intramuscular to standard atypical antipsychotic drug regimens monthly for three months.
In Group B, as control group, is received only standard atypical antipsychotic drug regimens. Patients in second group will be supplemented with vitamin D after the 3 months study period.
Sponsors
Vice chancellor for research,Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
19 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Schizophrenic patients based on DSM-IV TR criteria ;aged between 18 to 65 years; treated with atypical antipsychotic drugs except clozapine ; Vitamin D deficiency (serum vitamin D concentrations less than 30 ng/ml) . Exclusion criteria: Patients with Acute renal failure; hepatic failure; parathyroid disease and consumption of vitamin D; parathyroid hormone; calcium and phosphorous supplements
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Positive and Negative Syndrome Scale total score (PANSS). Timepoint: Baseline and first,second,third month. Method of measurement: PANSS Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum vitamin D concentration. Timepoint: Baseline and third month. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShima Mamashli
Mazandaran University of Medical Sciences
Outcome results
None listed